Fig. 6: Bicalutamide (Bic) decreases cellular viability and increases necrosis and apoptosis in HGC-27 and MGC-803 xenografts. | Cell Death & Disease

Fig. 6: Bicalutamide (Bic) decreases cellular viability and increases necrosis and apoptosis in HGC-27 and MGC-803 xenografts.

From: Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer

Fig. 6

A The flowchart showed the Xenograft model procedure for AR agnostic efficiency test. B Two weeks after inoculation, The AR protein expression of MGC-803 tumor samples from control (upper) and DHT (lower) treated mice were evaluated by immunohistochemistry (IHC). Scale bars represent 50 μm. C and D Representative images of tumor nodules in control (ctrl) and BIC (50 mg/Kg/Day) group of female (C) and male (D) xenograft model. Note: HGC-27 (left panel) and MGC-803 (right panel) xenografts were displayed respectively. Scale bar represents 1 cm. E and F Quantification of tumor nodule weights in control and BIC administrate group of mice of HGC-27 (left) and MGC-803 (right) in female (E) and male (F) xenograft model, error bars represent ±SD. G and H The growth curve of tumor xenografts in nude mice of HGC-27 (left) and MGC-803 (right) in female (G) and male (H) xenograft model, error bars represent ± SEM. I and J The AR and Ki-67 protein expression and apoptosis status of HGC-27(I) and MGC-803(J) in female xenograft model, tumor samples from control and BIC treated mice were evaluated by H&E staining, immunohistochemistry (IHC), and TUNEL assay. Scale bars represent 50 μm. K Quantification of AR and Ki-67 protein expression and TUNEL positive cells in HGC-27 (I) and MGC-803 (J) tumor samples of female xenograft model. Error bars represent ± SD. *Indicates significant difference P < 0.05.

Back to article page